Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy

BACKGROUND: Programmed Death Ligand 1 (PD-L1) is a co-stimulatory and immune checkpoint protein. PD-L1 expression in non-small cell lung cancers (NSCLC) is a hallmark of adaptive resistance and its expression is often used to predict the outcome of Programmed Death 1 (PD-1) and PD-L1 immunotherapy t...

Descripción completa

Detalles Bibliográficos
Autores principales: Brogden, Kim A., Parashar, Deepak, Hallier, Andrea R., Braun, Terry, Qian, Fang, Rizvi, Naiyer A., Bossler, Aaron D., Milhem, Mohammed M., Chan, Timothy A., Abbasi, Taher, Vali, Shireen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5897943/
https://www.ncbi.nlm.nih.gov/pubmed/29486723
http://dx.doi.org/10.1186/s12885-018-4134-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5897943/
https://www.ncbi.nlm.nih.gov/pubmed/29486723
http://dx.doi.org/10.1186/s12885-018-4134-y

Ejemplares similares